Meningococcal B — Competitive Intelligence Brief

Meningococcal B (Meningococcal B) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Immunology.

marketed vaccine Neisseria meningitidis serogroup B surface antigens (recombinant proteins) Immunology Biologic

Target snapshot

Meningococcal B (Meningococcal B) — Canadian Immunization Research Network. Meningococcal B vaccine stimulates the immune system to produce antibodies against serogroup B Neisseria meningitidis, preventing meningococcal disease.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Meningococcal B TARGET	Meningococcal B	Canadian Immunization Research Network	marketed	vaccine	Neisseria meningitidis serogroup B surface antigens (recombinant proteins)
Comirnaty	BNT162b2 (tozinameran)	Pfizer Inc.	marketed	vaccine	SARS-CoV-2 virus	2021-08-23
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
Meningococcal A (control)	Meningococcal A (control)	International Vaccine Institute	marketed	polysaccharide vaccine	Neisseria meningitidis serogroup A capsular polysaccharide
Comparator: PedvaxHIB™	Comparator: PedvaxHIB™	Merck Sharp & Dohme LLC	marketed	Conjugate vaccine	Haemophilus influenzae type b polyribosylribitol phosphate (PRP) capsular polysaccharide
Havrix+Healive	Havrix+Healive	Sinovac Biotech Co., Ltd	marketed	Combination inactivated viral vaccine	Hepatitis A virus antigen; Hepatitis B surface antigen (HBsAg)
PCRA (Intermittent injection)	PCRA (Intermittent injection)	Örebro University, Sweden	marketed	Cancer vaccine / Autologous cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
• 2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (vaccine class)

1. Pfizer · 20 drugs in this class
2. Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
3. GlaxoSmithKline · 12 drugs in this class
4. Merck Sharp & Dohme LLC · 12 drugs in this class
5. Centers for Disease Control and Prevention · 9 drugs in this class
6. Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
7. Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
8. Beijing Center for Disease Control and Prevention · 6 drugs in this class
9. International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
10. Sinovac Biotech Co., Ltd · 4 drugs in this class